Citations

Mayo Clinic

Showing 10 of 108403 citations.

Acetylcholine in the cerebral cortex
Benarroch, Eduardo E.

Neurology | August 16, 2010 | Volume: 75 | Issue: 7 | Pages: 659-665

10.1212/wnl.0b013e3181ee267e | PMID 20713954 Get It

A Qualitative and Quantitative Comparison of Two Rubella Virus-Specific IgG Antibody Immunoassays
Greenwood, Nicholas P., Ovsyannikova, Inna G. , Vierkant, Robert A. , O’Byrne, Megan M., Poland, Gregory A. , Vierkant, Robert A

Viral Immunology | August 16, 2010 | Volume: 23 | Issue: 4 | Pages: 353-357

10.1089/vim.2010.0026 | PMID 20712479 Get It

Pathogenesis of Fasting and Postprandial Hyperglycemia in Type 2 Diabetes: Implications for Therapy
Rizza, Robert A.

Diabetes | August 13, 2010 | Volume: 59 | Issue: 11 | Pages: 2697-2707

10.2337/db10-1032 | PMID 20705776 Get It

The objective of this research is to gain a greater understanding of the cause of fasting and postprandial hyperglycemia in people with type 2 diabetes. Endogenous glucose production is excessive before eating and fails to appropriately suppress after eating in people with type 2 diabetes. This is due in part to impaired insulin-induced suppression of endogenous glucose production, which is observed early in the evolution of type 2 diabetes. Increased rates of gluconeogenesis and perhaps glycogenolysis contribute to hepatic insulin resistance. Insulin-induced stimulation of hepatic glucose uptake and hepatic glycogen synthesis are reduced in people with type 2 diabetes primarily due to decreased uptake of extracellular glucose presumably because of inadequate activation of hepatic glucokinase. Delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulin resistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulin resistance are present. The premise of these studies, as well as those performed by many other investigators, is that an understanding of the pathogenesis of type 2 diabetes will enable the development of targeted therapies that are directed toward correcting specific metabolic defects in a given individual. I, as well as many other investigators, believe that such therapies are likely to be more effective and to have a lower risk than would occur if everyone were treated the same regardless of the underlying cause of their hyperglycemia. While we do not yet have sufficient knowledge to truly individualize therapy, in my opinion this approach will be the norm in the not too distant future.
Short-Term Cardiac and Noncardiac Mortality Following Liver Transplantation
Eleid, Mackram F. , Hurst, R. Todd, Vargas, Hugo E. , Rakela, Jorge , Appleton, Christopher P., Mulligan, David C. , Vargas, Hugo E

Journal of Transplantation | August 12, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-7

10.1155/2010/910165 | PMID 20814597 Get It

Objectives. To determine the importance of acute cardiac events as a cause of mortality compared to non-cardiac events in the four month period following liver transplantation (LT) using current preoperative cardiac screening strategies.Patients and Methods. We retrospectively reviewed timing, type, and outcome of adverse cardiac events, and all cause mortality in the 4 month postoperative period in 393 consecutive LT patients from October 1999 to February 2008.Results. Of 30 total deaths (7.6% overall mortality rate), 27 (90%) were due to surgical or medical complications and 3 (10%) were primary cardiac deaths (0.8% cardiac mortality rate). Acute cardiac events occurred in 26 patients (6.6%), including 13 arrhythmias (50%), 7 new onset heart failures (27%), and 6 myocardial infarctions (23%). Twelve of 13 intraoperative events were arrhythmias (92%) including two of three cardiac deaths.Conclusions. Using current preoperative screening recommendations, deaths from primary cardiac events within four months of LT are very uncommon (0.8%), especially compared with deaths related to medical and surgical complications (6.9%).
Heme oxygenase activity as a determinant of the renal hemodynamic response to low-dose ANG II
Nath, Karl A. , Hernandez, Melissa C., Croatt, Anthony J., Katušić, Zvonimir S. , Juncos, Luis A. , Juncos, Luis A

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | August 12, 2010 | Volume: 299 | Issue: 5 | Pages: R1183-R1191

10.1152/ajpregu.00212.2010 | PMID 20702802 Get It

ANG II causes renal injury through hemodynamic and other effects, and pressor doses of ANG II induce heme oxygenase-1 (HO-1) as a protective response. The present studies examined the hemodynamic effects of more clinically relevant, lower doses of ANG II and the role of HO activity in influencing these effects. Under euvolemic conditions, ANG II increased arterial pressure and renal vascular resistance. ANG II did not induce oxidative stress, inflammation/injury-related gene expression, or proteinuria and did not alter extrarenal vascular reactivity. At these doses, ANG II failed to increase HO-1 or HO-2 mRNA expression or HO activity. Inhibiting HO activity in ANG II-treated rats by tin mesoporphyrin further increased renal vascular resistances, decreased renal blood flow, and blunted the rise in arterial pressure without inducing oxidative stress or altering expression of selected vasoactive/injury/inflammation-related genes; tin mesoporphyrin did not alter vasorelaxation of mesenteric resistor vessels. We conclude that in this model renal vasoconstriction occurs without the recognized adverse effects of ANG II on glomerular filtration rate, renal blood flow, oxidative stress, vascular reactivity, proteinuria, and injury-related gene expression; renal HO activity is essential in preserving perfusion of the ANG II-exposed kidney. These findings represent an uncommon example wherein function of a stressed organ (by ANG II), but not that of the unstressed organ, requires intact renal HO activity, even when the imposed stress neither induces HO-1 nor HO activity. These findings may be germane to conditions attended by heightened ANG II levels, ineffective renal perfusion, and susceptibility to acute kidney injury.
Rapid Drug Susceptibility Testing with a Molecular Beacon Assay Is Associated with Earlier Diagnosis and Treatment of Multidrug-Resistant Tuberculosis in California
Banerjee, Ritu , Allen, Jennifer R. , Lin, S.-Y. Grace, Westenhouse, Janice, Desmond, Ed, Schecter, Gisela, Scott, Cheryl, Raftery, Ann, Mase, Sundari , Watt, James, Flood, Jennifer

Journal of Clinical Microbiology | August 12, 2010 | Volume: 48 | Issue: 10 | Pages: 3779-3781

10.1128/jcm.01236-10 | PMID 20702667 Get It

ABSTRACTTo assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR TB.
Mutations in the Stalk Region of the Measles Virus Hemagglutinin Inhibit Syncytium Formation but Not Virus Entry
Ennis, Matthew K., Hu, Chunling , Naik, Shruthi , Hallak, Louay K. , Peng, Kah Whye, Russell, Stephen J. , Dingli, David , Russell, Stephen J , Hu, Chunling , Dingli, David

Journal of Virology | August 12, 2010 | Volume: 84 | Issue: 20 | Pages: 10913-10917

10.1128/jvi.00789-10 | PMID 20702637 Get It

ABSTRACT Measles virus (MV) entry requires at least 2 viral proteins, the hemagglutinin (H) and fusion (F) proteins. We describe the rescue and characterization of a measles virus with a specific mutation in the stalk region of H (I98A) that is able to bind normally to cells but infects at a lower rate than the wild type due to a reduction in fusion triggering. The mutant H protein binds to F more avidly than the parent H protein does, and the corresponding virus is more sensitive to inhibition by fusion-inhibitory peptide. We show that after binding of MV to its receptor, H-F dissociation is required for productive infection.
Coordination of Substrate Binding and ATP Hydrolysis in Vps4-Mediated ESCRT-III Disassembly
Davies, Brian A., Azmi, Ishara F. , Payne, Johanna A., Shestakova, Anna , Horazdovsky, Bruce , Babst, Markus , Katzmann, David J.

Molecular Biology of the Cell | August 12, 2010 | Volume: 21 | Issue: 19 | Pages: 3396-3408

10.1091/mbc.e10-06-0512 | PMID 20702581 Get It

ESCRT-III undergoes dynamic assembly and disassembly to facilitate membrane exvagination processes including multivesicular body (MVB) formation, enveloped virus budding, and membrane abscission during cytokinesis. The AAA-ATPase Vps4 is required for ESCRT-III disassembly, however the coordination of Vps4 ATP hydrolysis with ESCRT-III binding and disassembly is not understood. Vps4 ATP hydrolysis has been proposed to execute ESCRT-III disassembly as either a stable oligomer or an unstable oligomer whose dissociation drives ESCRT-III disassembly. An in vitro ESCRT-III disassembly assay was developed to analyze Vps4 function during this process. The studies presented here support a model in which Vps4 acts as a stable oligomer during ATP hydrolysis and ESCRT-III disassembly. Moreover, Vps4 oligomer binding to ESCRT-III induces coordination of ATP hydrolysis at the level of individual Vps4 subunits. These results suggest that Vps4 functions as a stable oligomer that acts upon individual ESCRT-III subunits to facilitate ESCRT-III disassembly.
Insulin Receptor A and IGF-IR in AML – Response
Hendrickson, Andrea E. Wahner , Erlichman, Charles , Gottardis, Marco M. , Carboni, Joan M., Karp, Judith E. , Haluska, Paul , Kaufmann, Scott H.

Cancer Research | August 11, 2010 | Volume: 70 | Issue: 17 | Pages: 7010-7010

10.1158/0008-5472.can-10-1920 Get It

InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions
Turner, Jennifer , Morton, Lindsay M. , Linet, Martha S. , Vajdic, Claire M. , Monnereau, Alain, Marcos‐Gragera, Rafael , Costantini, Adele Seniori , Cerhan, James R. , Weisenburger, Dennis D. , Monnereau, Alain , Clarke, Christina A. , Kadin, Marshall E. , Maynadié, Marc , Chiu, Brian C.‐H. , Cerhan, James R , Turner, Jennifer , Vajdic, Claire M , Morton, Lindsay M , Marcos-Gragera, Rafael

Blood | August 11, 2010 | Volume: 116 | Issue: 20 | Pages: e90-e98

10.1182/blood-2010-06-289561 | PMID 20699439 Get It

Abstract After publication of the updated World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues in 2008, the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) now presents an update of the hierarchical classification of lymphoid neoplasms for epidemiologic research based on the 2001 WHO classification, which we published in 2007. The updated hierarchical classification incorporates all of the major and provisional entities in the 2008 WHO classification, including newly defined entities based on age, site, certain infections, and molecular characteristics, as well as borderline categories, early and “in situ” lesions, disorders with limited capacity for clinical progression, lesions without current International Classification of Diseases for Oncology, 3rd Edition codes, and immunodeficiency-associated lymphoproliferative disorders. WHO subtypes are defined in hierarchical groupings, with newly defined groups for small B-cell lymphomas with plasmacytic differentiation and for primary cutaneous T-cell lymphomas. We suggest approaches for applying the hierarchical classification in various epidemiologic settings, including strategies for dealing with multiple coexisting lymphoma subtypes in one patient, and cases with incomplete pathologic information. The pathology materials useful for state-of-the-art epidemiology studies are also discussed. We encourage epidemiologists to adopt the updated InterLymph hierarchical classification, which incorporates the most recent WHO entities while demonstrating their relationship to older classifications.